IP6K2 mutations as a novel mechanism of resistance to oncolytic virus therapy.

ABSTRACT:

Background

Oncolytic virus therapy (OVT) represents a promising frontier in cancer treatment. Despite its efficacy in clinical trials, variability in patient response, particularly resistance development, highlights the need for tailored therapeutic strategies.

Methods

The Inositol Hexakisphosphate Kinase 2 (IP6K2) gene knock out was carried by CRISPR/Cas9 system. The evaluation of biomarkers of apoptosis and relevant pathways was conducted to be assessed. Attachment assay was conducted to verify the binding ability of virus to the host cells. Cell proliferation and apoptosis was assessed. Subcutaneous xenograft model was used to evaluate IP6K2 knock out influence in vivo. cBioPortal and TCGA database were applied to analyze genomic alterations in pan-cancer.

Results

SUBMITTER: Huang Z 

PROVIDER: S-EPMC11900485 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature